Fox Run Management, L.L.C. Incyte Corp Transaction History

Fox Run Management, L.L.C.

$433 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$51.18 - $63.75 $37,924 - $47,238	-741 Reduced 4.5%	15,710 $952,000
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $930,304 - $1.1 Million	16,451 New	16,451 $937,000
Q3 2023 Nov 07, 2023	BUY	$57.77 - $65.93 $302,021 - $344,682	5,228 New	5,228 $302,000
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $167,990 - $205,735	2,392 Added 41.39%	8,171 $590,000
Q4 2022 Feb 07, 2023	BUY	$67.18 - $84.11 $388,233 - $486,071	5,779 New	5,779 $464,000
Q1 2022 May 10, 2022	SELL	$66.02 - $79.71 $625,539 - $755,252	-9,475 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$63.34 - $74.11 $264,571 - $309,557	4,177 Added 78.84%	9,475 $695,000
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $120,859 - $147,875	1,760 Added 49.75%	5,298 $364,000
Q2 2021 Aug 05, 2021	BUY	$79.87 - $87.53 $282,580 - $309,681	3,538 New	3,538 $298,000
Q1 2020 May 08, 2020	SELL	$63.18 - $85.97 $417,367 - $567,917	-6,606 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $220,434 - $288,882	3,018 Added 84.11%	6,606 $577,000
Q3 2019 Oct 15, 2019	BUY	$72.82 - $86.52 $261,278 - $310,433	3,588 New	3,588 $266,000
Q4 2018 Jan 15, 2019	SELL	$58.5 - $69.94 $623,785 - $745,770	-10,663 Closed	0 $0
Q3 2018 Oct 05, 2018	SELL	$61.75 - $74.23 $410,699 - $493,703	-6,651 Reduced 38.41%	10,663 $737,000
Q2 2018 Jul 17, 2018	BUY	$60.85 - $83.98 $139,650 - $192,734	2,295 Added 15.28%	17,314 $1.16 Million
Q1 2018 Apr 17, 2018	BUY	$83.06 - $100.98 $1.02 Million - $1.24 Million	12,314 Added 455.23%	15,019 $1.25 Million
Q4 2017 Jan 18, 2018	SELL	$93.56 - $116.6 $252,144 - $314,237	-2,695 Reduced 49.91%	2,705 $256,000
Q3 2017 Oct 23, 2017	BUY	$109.15 - $138.27 $589,410 - $746,658	5,400	5,400 $630,000

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Account